Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
BackgroundThe use of checkpoint inhibitors has revolutionized cancer therapy. Unfortunately, these therapies often cause immune-related adverse effects, largely due to a lack of tumor specificity.MethodsWe stained human natural killer cells using fusion proteins composed of the extracellular portion...
Saved in:
Published in | Journal for immunotherapy of cancer Vol. 8; no. 1; p. e000266 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group LTD
01.06.2020
BMJ Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!